The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Slack Technologies' reference price was set at $26 per share, the New York Stock Exchange announced Wednesday evening.Technologyread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
With the Federal Reserve deciding not to cut interest rates but leaving the door open for future cuts, experts are split on what comes next.Trading Nationread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social CapitalTechnologyread more
Investors need to be cautious because the economy will get hurt the longer the trade war drags on, Jim Cramer says.Mad Money with Jim Cramerread more
Oracle found revenue growth from cloud applications in its fiscal fourth quarter, which helped it surpass analysts' expectations.Technologyread more
Sarepta Therapeutics CEO Doug Ingram told CNBC on Wednesday that accessing reimbursement from insurance companies for expensive, rare disease treatments is "always challenging."
But responding to a question about the $300,000-per-year cost for a Sarepta drug for Duchenne muscular dystrophy, Ingram defended the price tag.
"Sarepta is a small company. We have already invested $1 billion fighting Duchenne muscular dystrophy. And we're not done yet," he said on "Squawk Box."
Exondys 51 was approved for DMD on a conditional basis by the Food and Drug Administration last year, pending more testing to confirm results. It treats a mutation affecting about 13 percent of sufferers. The cost per-year is about $300,000 for a 55-pound patient. The price goes up for heavier recipients.
"This a societal question more than a Sarepta question," Ingram said. "I think it's the right decision for society to invest in finding solutions for these rare disorders."
Shares of Sarepta, which had a stock market value of $2.6 billion as of Tuesday's close on Wall Street, soared 9 percent Wednesday morning. It had risen 17 percent in premarket trading after the biopharma firm reported positive results from a clinical trial of another experimental DMD medicine. The treatment, golodirsen, targets a genetic mutation affecting about 8 percent of patients.
"Our goal is to treat 100 percent" of DMD suffers, said Ingram, who was appointed CEO of Sarepta in July. "The data that we have this morning shows we're on the right path."